ArticleCancer science2025

Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma.

Kanami Mori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.